Medifast (MED): A Bull Case Theory

Insider Monkey09-12

We came across a bullish thesis on Medifast (MED) on Value Degen’s Substack by Unemployed Value Degen. In this article we will summarize the bulls’ thesis on MED. Medifast, Inc. share was trading at $...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2466325599?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Hvc3W3cZK94pwqVEJFuN0g--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/9ce4281d9293b50790976a6967cd8364","is_english":true,"pubTime":"2024-09-12 02:01","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2466325599","market":"us","top_or_hot":-1,"title":"Medifast (MED): A Bull Case Theory","media":"Insider Monkey","content":"<div>\n<p>We came across a bullish thesis on Medifast (MED) on Value Degen’s Substack by Unemployed Value Degen. In this article we will summarize the bulls’ thesis on MED. Medifast, Inc. share was trading at $...</p>\n\n<a href=\"https://finance.yahoo.com/news/medifast-med-bull-case-theory-180138202.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Medifast (MED): A Bull Case Theory</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMedifast (MED): A Bull Case Theory\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-12 02:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/medifast-med-bull-case-theory-180138202.html><strong>Insider Monkey</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>We came across a bullish thesis on Medifast (MED) on Value Degen’s Substack by Unemployed Value Degen. In this article we will summarize the bulls’ thesis on MED. Medifast, Inc. share was trading at $...</p>\n\n<a href=\"https://finance.yahoo.com/news/medifast-med-bull-case-theory-180138202.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4183","symbol_name":"个人用品","start_time":0,"source_url":"https://finance.yahoo.com/news/medifast-med-bull-case-theory-180138202.html","article_id":"2466325599","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Hvc3W3cZK94pwqVEJFuN0g--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/9ce4281d9293b50790976a6967cd8364"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2466325599","pubTimestamp":1726077698,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"We came across a bullish thesis on Medifast  on Value Degen’s Substack by Unemployed Value Degen. In this article we will summarize the bulls’ thesis on MED. Medifast, Inc. share was trading at $18.51 as of Sept 6.Despite suspending its dividend to preserve cash, Medifast maintains a strong balance sheet with $150 million in cash and no debt. While there are risks, including insider selling and potential disproportionate benefits to LifeMD, MED could potentially see a return to its previous revenue levels if it successfully captures new market segments. This turnaround story is uncertain, but for value-oriented investors, Medifast offers a compelling risk/reward profile for a small position while awaiting fu","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4183":"个人用品","NVO":"诺和诺德","LFMD":"LifeMD Inc.","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","MED":"快验保","BK4167":"医疗保健技术","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4007":"制药","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4588":"碎股","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","BK4532":"文艺复兴科技持仓"},"translate_title":"快验保(MED)：牛市案例理论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LFMD":1,"MED":1,"NVO":1},"content_text":"We came across a bullish thesis on Medifast (MED) on Value Degen’s Substack by Unemployed Value Degen. In this article we will summarize the bulls’ thesis on MED. Medifast, Inc. share was trading at $18.51 as of Sept 6.\n michaeljung/Shutterstock.com \nMedifast (MED) was once a key player in the $7 billion structured weight loss program market, with revenues of $1.6 billion and net income of $143 million in 2022. However, the company's fortunes have declined sharply amid a new medical weight loss revolution led by Novo Nordisk's (NVO) Ozempic and other GLP-1 competitors. Medifast’s share price has plummeted from $332 to $21.30, while net income fell to $67 million and revenue dropped to $900 million. This decline raises questions about whether GLP-1 drugs have rendered Medifast’s platform obsolete or if MED can adapt to the changing market landscape.\nMedifast operates like a cross between Herbalife and Alcoholics Anonymous, combining multilevel marketing with a behavioral psychology approach to weight loss. Despite the negative reputation of multilevel marketing, MED's model involves a sophisticated system for changing habits, utilizing techniques like high upfront costs, one-on-one coaching, and progress-tracking apps to create accountability and encourage success. Yet, GLP-1 drugs, while effective for weight loss, come with challenges such as muscle loss, the need for lifestyle changes, and nutritional supplements—areas where Medifast could still play a role.\nTo adapt, MED is transforming its business model to align with the GLP-1 weight loss trend. It has entered the $30 billion sports nutrition market and partnered with LifeMD (LFMD) to integrate its services with medical weight loss. This partnership includes access to LFMD’s doctors for GLP-1 prescriptions and related medical support, while Medifast provides coaching, lifestyle guidance, and nutritional supplements, all tracked via its Optavia app. MED aims to capture a share of the growing GLP-1 supplement market, projected to reach $50 billion by 2032.\nMedifast's new strategy is currently being rolled out, with a $25 million advertising budget for 2024. Although there are challenges, including reduced program costs and the potential for slow uptake, the company is positioning itself in two expanding markets with a combined size of $80 billion. Furthermore, changes in how GLP-1 drugs are paid for, including potential Medicare and insurance coverage, could make Medifast's services more competitive.\nDespite suspending its dividend to preserve cash, Medifast maintains a strong balance sheet with $150 million in cash and no debt. While there are risks, including insider selling and potential disproportionate benefits to LifeMD, MED could potentially see a return to its previous revenue levels if it successfully captures new market segments. This turnaround story is uncertain, but for value-oriented investors, Medifast offers a compelling risk/reward profile for a small position while awaiting further traction in its new strategy.\nMedifast is not on our list of the 31 Most Popular Stocks Among Hedge Funds. As per our database, 16 hedge fund portfolios held MED at the end of the second quarter which was 14 in the previous quarter. While we acknowledge the potential of MED as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as MED but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.\nREAD NEXT: Analyst Sees a New $25 Billion “Opportunity” for NVIDIA and 10 Best of Breed Stocks to Buy For The Third Quarter of 2024 According to Bank of America. Disclosure: None.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2466325599"}